Therapeutic Efficacy and Tolerance of Ramipril in Hypertensive Patients with Renal Failure

Kindler, Jochen; Schunkert, Heribert; Gassmann, Martin; Lahn, W.; Irmisch, R; Debusmann, E. R.; Ocón-Pujadas, J; Ritz, Eberhard; Sieberth, H. G.

doi:10.1097/00005344-198900133-00014

Journal of Cardiovascular Pharmacology

1989

DOI: 10.1097/00005344-198900133-00014

|View full text |Cite

Therapeutic Efficacy and Tolerance of Ramipril in Hypertensive Patients with Renal Failure

Jochen Kindler¹,

Heribert Schunkert²,

Martin Gassmann³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1991

2011

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ramipril is a potent and long-acting angiotensin-converting enzyme (ACE) inhibitor [1][2][3] that is used for treatment of essential hypertension [4][5][6][7] and congestive heart failure [8,9]. Clinical trials in patients with mild to moderate hypertension demonstrated that treatment with a single daily dose of 2.5-5 mg ramipril was effective in two-thirds of hypertensive patients [2,10,11].…”

mentioning

confidence: 99%

Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril

Griensven

Schoemaker

Cohen

et al. 1995

Eur J Clin Pharmacol

View full text Add to dashboard Cite

The pharmacokinetics and pharmacodynamics of the prodrug ramipril and its active ACE-inhibiting metabolite ramiprilat were investigated in an open, randomised, three-way cross-over study in 12 healthy male volunteers. Subjects received 2.5 mg ramipril orally, 2.5 mg ramipril intravenously and 2.5 mg ramiprilat intravenously. The absolute bioavailability as judged by ramipril plasma AUC was 15%, by ramiprilat plasma AUC, 44%. Ramiprilat formation from intravenous ramipril was 53% and from oral ramipril 28%. Urinary recovery of oral ramipril was 23%, i.v. ramipril 49%, and i.v. ramiprilat 68% of the given dose. Maximum ACE inhibition was highest (100%) after i.v. ramiprilat; it was 99% after i.v. ramipril and 84% following oral ramipril. ACE inhibition over 24 h was highest after i.v. ramipril, 2% less with i.v. ramiprilat and 34% less with oral ramipril. Ramiprilat renal clearance was concentration dependent. The biological availability of ramipril can best be judged by ramiprilat AUC, urinary recovery of ramipril and metabolites, or ACE inhibition over 24 h. It is concluded that the bioavailability of oral ramipril seems to be in the range of 44-66%.

show abstract

mentioning

confidence: 99%

Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril

Griensven

Schoemaker

Cohen

et al. 1995

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease

Sharma

Blackburn

Parke

et al. 2011

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

24‐hour blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: Magnitude and duration of antihypertensive effects

McCarron

1991

Clinical Cardiology

View full text Add to dashboard Cite

Summary:Ramipril is a new, potent nonsulfhydryl inhibitor of angiotensin converting enzyme. The magnitude and duration of its antihypertensive effect were evaluated in a multicenter, placebo-controlled, randomized clinical trial conducted in 100 patients with mild to moderate essential hypertension. Ramipril significantly reduced both supine and standing blood pressures measured 24 h after dosing. Automated blood pressure monitoring showed that ramipril significantly reduced systolic and diastolic pressures for 24 h after dosing. The peak effect occurred between 3 and 6 h after dosing, with approximately 50% of this efiect retained after 24 h. Ramipril was well tolerated; there was no significant difference between active drug and placebo in the overall incidence of side effects. Ramipril is an effective and well-tolerated antihypertensive agent, which reduces both supine and standing blood pressure over the entire 24-h period after dosing.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Therapeutic Efficacy and Tolerance of Ramipril in Hypertensive Patients with Renal Failure

Cited by 6 publications

References 0 publications

Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril

Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease

24‐hour blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: Magnitude and duration of antihypertensive effects

Contact Info

Product

Resources

About